Balloon‐Expandable Myval Octacor Versus Self‐Expanding Evolut PRO/PRO+ and Acurate Neo2: Short‐Term Outcomes From Propensity‐Matched Analysis

20251 citationsJournal Article

Authors

Elisabetta Moscarella · University of Campania "Luigi Vanvitelli"

Alfonso Ielasi · Istituto Clinico Sant'Ambrogio

Won‐Keun Kim · Kerckhoff Klinik

Rodolfo Caminiti · Istituto Clinico Sant'Ambrogio

Marco Barbanti · University of Catania

Arturo Giordano · Villa Pineta Hospital

Andreas Holzamer

Abstract

The Myval Octacor demonstrated comparable early safety and efficacy to supra-annular SEVs, with advantages in device success rate and hemodynamic performance. Adequately sized randomized study is required to confirm these findings.

Topics & Keywords

Cardiac Valve Diseases and Treatments Infective Endocarditis Diagnosis and Management Cardiovascular Function and Risk Factors

Publication Details

Published in: Catheterization and Cardiovascular Interventions

Volume 106, Issue 5, pp. 2949-2957

DOI: 10.1002/ccd.70097

Field-Weighted Citation Impact: 1.39

Command Palette

Balloon‐Expandable Myval Octacor Versus Self‐Expanding Evolut PRO/PRO+ and Acurate Neo2: Short‐Term Outcomes From Propensity‐Matched Analysis

Authors

Abstract

Topics & Keywords

Publication Details